3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
23
Carcinoma, Non-Small-Cell Lung
15
Prostatic Neoplasms
14
Stomach Neoplasms
12
Colorectal Neoplasms
12
Breast Neoplasms
12
Pancreatic Neoplasms
11
Leukemia, Myeloid, Acute
10
Neoplasm Metastasis
9
Lung Neoplasms
9
Hematologic Neoplasms
9
Head and Neck Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Hepatocellular
9
Squamous Cell Carcinoma of Head and Neck
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Ovarian Neoplasms
8
Myasthenia Gravis
7
Melanoma
7
Uterine Cervical Neoplasms
6
Recurrence
6
Rectal Neoplasms
6
Neoplasms by Site
6
Neoplasms by Histologic Type
6
Lymphoma
6
Leukemia
6
Urinary Bladder Neoplasms
5
Neoplasms, Plasma Cell
5
Infections
5
Colonic Neoplasms
5
Interventions
N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
Spinal Cord Injuries
×
Clear all
NCT05491525
2024-07-03
KANGUROO
Urovant Sciences GmbH
Phase 2/3
Recruiting
85 enrolled